Evidence map›Paper›PMID 34110899›Full record

ReviewCirculation research2021

New Directions in Therapeutic Angiogenesis and Arteriogenesis in Peripheral Arterial Disease.

Brian H Annex, John P Cooke

Open access · bronzeAbstract readReview
In one paragraph

Review in Circulation research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
118citing papers in PubMed, 1 pooled it
29.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

118 citing papers in PubMed, 1 synthesis or guideline pooled it, 201 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Direct in vivo reprogramming to relieve tissue ischemia via induced vasculogenesis.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review

58 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Brian H AnnexVascular Biology Center, Department of Medicine, Medical College of Georgia, Augusta University (B.H.A.).
John P CookeDepartment of Cardiovascular Sciences, Houston Methodist Research Institute, TX (J.P.C.).
Augusta University · USHouston Methodist · US

Funding

Systems Biology of Angiogenesis in Peripheral Arterial DiseaseR01HL101200 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI POPEL, ALEKSANDER S. · 2010 to 2022
$10.7M
Clinical Phenotyping and Disease Specific Sampling to Identify Non-coding RNAs for Human Therapeutics in PADR01HL150003 · NHLBI · AUGUSTA UNIVERSITY · PI ANNEX, BRIAN H, MCCLUNG, JOSEPH MATTHEW · 2020 to 2023
$3.0M
Precision Medicine for Therapeutic Angiogenesis in Peripheral Arterial Disease: Targeting of the IL21R PathwayR01HL148590 · NHLBI · AUGUSTA UNIVERSITY · PI ANNEX, BRIAN H · 2019 to 2022
$2.9M
Reversal of Heart Failure: Role of Vascular RecoveryR01HL148338 · NHLBI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CHEN, KAIFU, COOKE, JOHN P · 2020 to 2023
$2.8M
The Anti-angiogenic VEGF165b and VEGFR1 Signaling in Peripheral Artery DiseaseR01HL141325 · NHLBI · UNIVERSITY OF VIRGINIA · PI ANNEX, BRIAN H · 2019 to 2022
$2.7M
New Roles for VEGFR1 in AngiogenesisR01GM129074 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI MAC GABHANN, FEILIM C · 2018 to 2021
$2.6M
Role of S-nitrosylation in TransdifferentiationR01HL133254 · NHLBI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CHEN, KAIFU, COOKE, JOHN P · 2018 to 2021
$1.6M
NHLBI NIH HHS R01 HL101200NHLBI NIH HHS R01 HL133254NHLBI NIH HHS R01 HL141325NHLBI NIH HHS R01 HL148338NHLBI NIH HHS R01 HL148590NHLBI NIH HHS R01 HL150003NIGMS NIH HHS R01 GM129074
6 · The paper itself

Abstract

The prevalence of peripheral arterial disease (PAD) in the United States exceeds 10 million people, and PAD is a significant cause of morbidity and mortality across the globe. PAD is typically caused by atherosclerotic obstructions in the large arteries to the leg(s). The most common clinical consequences of PAD include pain on walking (claudication), impaired functional capacity, pain at rest, and loss of tissue integrity in the distal limbs that may lead to lower extremity amputation. Patients with PAD also have higher than expected rates of myocardial infarction, stroke, and cardiovascular death. Despite advances in surgical and endovascular procedures, revascularization procedures may be suboptimal in relieving symptoms, and some patients with PAD cannot be treated because of comorbid conditions. In some cases, relieving obstructive disease in the large conduit arteries does not assure complete limb salvage because of severe microvascular disease. Despite several decades of investigational efforts, medical therapies to improve perfusion to the distal limb are of limited benefit. Whereas recent studies of anticoagulant (eg, rivaroxaban) and intensive lipid lowering (such as PCSK9 [proprotein convertase subtilisin/kexin type 9] inhibitors) have reduced major cardiovascular and limb events in PAD populations, chronic ischemia of the limb remains largely resistant to medical therapy. Experimental approaches to improve limb outcomes have included the administration of angiogenic cytokines (either as recombinant protein or as gene therapy) as well as cell therapy. Although early angiogenesis and cell therapy studies were promising, these studies lacked sufficient control groups and larger randomized clinical trials have yet to achieve significant benefit. This review will focus on what has been learned to advance medical revascularization for PAD and how that information might lead to novel approaches for therapeutic angiogenesis and arteriogenesis for PAD.

Indexed as

Adult Stem CellsAmputation, SurgicalAngiogenesis Inducing AgentsAngiogenesis Modulating AgentsAnimalsAnticoagulantsAtherosclerosisEndothelium, VascularEndovascular ProceduresHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIntermittent ClaudicationLimb SalvageLower ExtremityMiceMicrocirculationAngiogenesis Inducing AgentsAngiogenesis Modulating AgentsAnticoagulantsHydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 protein, humanProprotein Convertase 9RNA, Untranslatedcytokinesmetabolismmicrovesselspermeabilitystem cells

Identifiers

PMID34110899
PMCPMC8538391
OpenAlexW3166518985

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.